{"id":"taxane-plus-intermittent-capecitabine","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Neutropenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"10-30","effect":"Hand-foot syndrome"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Taxanes (such as paclitaxel or docetaxel) stabilize microtubules and prevent their depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Capecitabine is a fluoropyrimidine prodrug that is converted to 5-fluorouracil, inhibiting thymidylate synthase and disrupting DNA synthesis. The intermittent dosing schedule of capecitabine is designed to reduce cumulative toxicity while maintaining efficacy.","oneSentence":"A combination regimen that uses taxane chemotherapy to disrupt microtubule dynamics and kill rapidly dividing cancer cells, paired with intermittent capecitabine to provide additional cytotoxic activity and potentially improve tolerability through dosing intermittency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:41.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"},{"name":"Other solid tumors (under investigation in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT05172518","phase":"PHASE3","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-03-01","conditions":"Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer","enrollment":512},{"nctId":"NCT01917279","phase":"PHASE3","title":"Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC","status":"UNKNOWN","sponsor":"Binghe Xu","startDate":"2013-10","conditions":"Breast Neoplasms, Neoplasms by Site, Neoplasm Metastasis","enrollment":280},{"nctId":"NCT01935492","phase":"PHASE3","title":"8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Borstkanker Onderzoek Groep","startDate":"2010-11","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer","enrollment":420},{"nctId":"NCT00532714","phase":"PHASE2","title":"Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2006-08","conditions":"Breast Cancer Metastatic","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Taxane plus Intermittent Capecitabine","genericName":"Taxane plus Intermittent Capecitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination regimen that uses taxane chemotherapy to disrupt microtubule dynamics and kill rapidly dividing cancer cells, paired with intermittent capecitabine to provide additional cytotoxic activity and potentially improve tolerability through dosing intermittency. Used for Metastatic breast cancer, Gastric cancer, Other solid tumors (under investigation in phase 3 trials).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}